EVO756 inhibits activation of MRGPRX2 in several in vitro models and correlates to human in vivo data

Evommune Inc. published this content on December 03, 2024, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 03, 2026 at 22:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]